Figure 3.

Linear in vivo growth of glioma after endothelial ephrinB2 knockout. (a) Experimental overview of the knockout induction and therapy experiments performed. (b) Coronal T2 MR images of tumor bearing mice 7, 14 and 19 days post-tumor cell injection of GL261 murine glioma cells. (c) T2 MR image analysis quantified a reduction in tumor growth in control animal after sunitinib therapy. Linear growth expansion of GL261 glioma was observed after endothelial specific ephrinB2 knockout (efnb2^i∆EC). Exponential growth characteristics were found in control animals (efnb2^lox/lox). The size between placebo control efnb2^lox/lox and sunitinib control efnb2^lox/lox (**** p < 0.0001) tumors and sunitinib control efnb2^lox/lox and placebo efnb2^i∆EC (* p = 0.0107) tumors was significant (two-way ANOVA, Sidak post hoc multiple comparisons test).